2.16.840.1.113883.5.1070/static-2012-07-24: Unterschied zwischen den Versionen

Aus Hl7wiki
Wechseln zu: Navigation, Suche
(Automated TermBot page content)
 
(Automated TermBot page content)
Zeile 67: Zeile 67:
 
|<font color="grey">(en-US)</font> none
 
|<font color="grey">(en-US)</font> none
 
| colspan="2" |<p>No substitution occurred or is permitted.</p>
 
| colspan="2" |<p>No substitution occurred or is permitted.</p>
 +
|}

Version vom 20. Oktober 2012, 12:11 Uhr

Codesystem Name Codesystem Id Version / Eingangsdatum Status
substanceAdminSubstitution 2.16.840.1.113883.5.1070 2012-07-24 definitiv
Level/Typ Code Anzeigename Beschreibung
0-A _ActSubstanceAdminSubstitutionCode (en-US) ActSubstanceAdminSubstitutionCode

Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.

1-S E (en-US) equivalent

Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

2-S EC (en-US) equivalent composition

Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril

3-L BC (en-US) brand composition

Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven

3-L G (en-US) generic composition

Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)

2-S TE (en-US) therapeutic alternative

Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet

3-L TB (en-US) therapeutic brand

Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics> Examples: Zantac for Tagamet

3-L TG (en-US) therapeutic generic

Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands> Examples: Ranitidine for cimetidine

1-L F (en-US) formulary

Description: This substitution was performed or is permitted based on formulary guidelines.

1-L N (en-US) none

No substitution occurred or is permitted.